SEC Comment Letter 0000000000-23-006046 to INTENSITY THERAPEUTICS, INC. (INTS)
INTENSITY THERAPEUTICS, INC.
Date: June 7, 2023 · CIK: 0001567264 · Accession: 0000000000-23-006046
AI Filing Summary & Sentiment
File numbers found in text: 333-260565
Letter
United States securities and exchange commission logo June 7, 2023 Lewis Bender Chief Executive Officer Intensity Therapeutics, Inc. 61 Wilton Road, 3rd Floor Westport, CT 06880 Re:Intensity Therapeutics, Inc. Amendment No. 13 to Registration Statement on Form S-1 Filed May 18, 2023 File No. 333-260565 Dear Lewis Bender: We have reviewed your amended registration statement and have the following comments. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure. Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe our comments apply to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response. After reviewing any amendment to your registration statement and the information you provide in response to these comments, we may have additional comments. Amendment No. 13 to Form S-1 filed May 18, 2023 Facilities, page 101 1.We note your disclosure on page 101 that you have provided notice that the Westport lease would terminate on June 30, 2023. However, you also disclose on page F-43 that the lease expires as of September 2023. Please clarify the term of the lease and revise accordingly. Please also file the lease agreement as an exhibit to the registration statement pursuant to Item 601(b)(10) of Regulation S-K. You may contact Sasha Parikh at 202-551-3627 or Al Pavot at 202-551-3738 if you have questions regarding comments on the financial statements and related matters. Please contact Jane Park at 202-551-7439 or Suzanne Hayes at 202-551-3675 with any other questions.
FirstName LastNameLewis Bender Comapany NameIntensity Therapeutics, Inc. June 7, 2023 Page 2 FirstName LastName Lewis Bender Intensity Therapeutics, Inc. June 7, 2023 Page 2 Sincerely, Division of Corporation Finance Office of Life Sciences cc: Daniel Woodard, Esq.
Show Raw Text
United States securities and exchange commission logo
June 7, 2023
Lewis Bender
Chief Executive Officer
Intensity Therapeutics, Inc.
61 Wilton Road, 3rd Floor
Westport, CT 06880
Re:Intensity Therapeutics, Inc.
Amendment No. 13 to Registration Statement on Form S-1
Filed May 18, 2023
File No. 333-260565
Dear Lewis Bender:
We have reviewed your amended registration statement and have the following
comments. In some of our comments, we may ask you to provide us with information so we
may better understand your disclosure.
Please respond to this letter by amending your registration statement and providing the
requested information. If you do not believe our comments apply to your facts and
circumstances or do not believe an amendment is appropriate, please tell us why in your
response.
After reviewing any amendment to your registration statement and the information you
provide in response to these comments, we may have additional comments.
Amendment No. 13 to Form S-1 filed May 18, 2023
Facilities, page 101
1.We note your disclosure on page 101 that you have provided notice that the Westport
lease would terminate on June 30, 2023. However, you also disclose on page F-43 that
the lease expires as of September 2023. Please clarify the term of the lease and revise
accordingly. Please also file the lease agreement as an exhibit to the registration statement
pursuant to Item 601(b)(10) of Regulation S-K.
You may contact Sasha Parikh at 202-551-3627 or Al Pavot at 202-551-3738 if you have
questions regarding comments on the financial statements and related matters. Please contact
Jane Park at 202-551-7439 or Suzanne Hayes at 202-551-3675 with any other questions.
FirstName LastNameLewis Bender
Comapany NameIntensity Therapeutics, Inc.
June 7, 2023 Page 2
FirstName LastName
Lewis Bender
Intensity Therapeutics, Inc.
June 7, 2023
Page 2
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Daniel Woodard, Esq.